$ERAS earnings report

Erasca reports Q3 2026 net loss of $51.3 million as R&D spend rises; cash of $947.8 million; ERAS-0015 receives FDA Fast Track Designation for metastatic pancreatic adenocarcinoma. AlphAI read Erasca's Q3 FY2026 filing as mixed. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readERAS · Q3 2026 · ended 2026-09-30

Erasca reports Q3 2026 net loss of $51.3 million as R&D spend rises; cash of $947.8 million; ERAS-0015 receives FDA Fast Track Designation for metastatic pancreatic adenocarcinoma

→Mixed quarter

The filing reports no revenue line. Net loss widened from $30.6 million to $51.3 million, with R&D up from $22.5 million to $47.2 million, and nine-month results include $150.0 million of in-process R&D. Cash, cash equivalents and marketable securities rose to $947.8 million from $341.8 million at December 31, 2025, and the company states this is sufficient to fund its listed milestones.

EPS · GAAP
$(0.15)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expense, Q3 2026 (three months ended September 30, 2026)GAAP$47.2M––
General and administrative expense, Q3 2026 (three months ended September 30, 2026)GAAP$12.3M––
In-process research and development, Q3 2026 (three months ended September 30, 2026)GAAPno amount shown (dash in statement of operations)––
Total operating expenses, Q3 2026 (three months ended September 30, 2026)GAAP59.52M––
Loss from operations, Q3 2026 (three months ended September 30, 2026)GAAP−59.52M––
Interest income, Q3 2026 (three months ended September 30, 2026)GAAP8.26M––
Total other income (expense), net, Q3 2026 (three months ended September 30, 2026)GAAP8.19M––
Net loss, Q3 2026 (three months ended September 30, 2026)GAAP$51.3M––
Net loss per share, basic and diluted, Q3 2026 (three months ended September 30, 2026)GAAP$(0.15)––
Comprehensive loss, Q3 2026 (three months ended September 30, 2026)GAAP−54.27M––
Research and development expense, nine months 2026 (nine months ended September 30, 2026)GAAP110.4M––
In-process research and development, nine months 2026 (nine months ended September 30, 2026)GAAP150M––
General and administrative expense, nine months 2026 (nine months ended September 30, 2026)GAAP34.69M––
Total operating expenses, nine months 2026 (nine months ended September 30, 2026)GAAP295.1M––
Loss from operations, nine months 2026 (nine months ended September 30, 2026)GAAP−295.1M––
Interest income, nine months 2026 (nine months ended September 30, 2026)GAAP16.32M––
Total other income (expense), net, nine months 2026 (nine months ended September 30, 2026)GAAP16.20M––
Net loss, nine months 2026 (nine months ended September 30, 2026)GAAP−278.9M––
Net loss per share, basic and diluted, nine months 2026 (nine months ended September 30, 2026)GAAP$(0.87)––
Comprehensive loss, nine months 2026 (nine months ended September 30, 2026)GAAP−283.7M––
Cash, cash equivalents, and marketable securities (as of September 30, 2026)other$947.8M––
Total assets (as of September 30, 2026)other998.9M––
Total stockholders' equity (as of September 30, 2026)other916.7M––

Capital returns

  • No share repurchases or dividends are reported in the filing.

What drove it

  • The company states that the R&D increase was primarily driven by higher expenses for clinical trials, preclinical studies, discovery activities, personnel costs including stock-based compensation, outsourced services, and consulting fees.
  • The company states that the G&A increase was primarily driven by personnel costs, including stock-based compensation expense.
  • The filing reports that interest income was 8,264 (in thousands) in Q3 2026 against 3,971 (in thousands) in Q3 2025, and that other income (expense) is shown net within total other income.
  • The filing reports 150,000 (in thousands) of in-process R&D for the nine months ended September 30, 2026, against 9,500 (in thousands) in the prior-year nine months, and no in-process R&D amount in Q3 2026.

Concerns

  • Net loss increased from $30.6 million to $51.3 million in the quarter, and nine-month net loss reached (278,850) (in thousands) against (95,454) (in thousands) in the prior-year period.
  • The filing reports no revenue line in its statements of operations.
  • Nine-month results include 150,000 (in thousands) of in-process R&D expense, which the filing presents within operating expenses.
  • The forward-looking statements list the possibility that the company may not successfully defend allegations raised by Revolution Medicines (RevMed) that ERAS-0015 infringes RevMed patents or was derived from RevMed trade secrets, and note that future litigation may be initiated.
  • The timing of the Phase 3 pivotal trial in RASm NSCLC is given as the second half of 2027 to the first half of 2028, and the forward-looking statements note that planned trials may be delayed based on FDA feedback or requirements.
  • The forward-looking statements caution that interim, topline and preliminary results may materially change, and that the FDA retains broad discretion to require additional clinical data before a registrational trial.

What to watch

  • ENA Symposium presentations, November 18 to 20, 2026 in Barcelona: an oral plenary with updated ERAS-0015 monotherapy data from AURORAS-1, and a poster on nonclinical ERAS-0015 and ERAS-4001 combination data.
  • Preliminary ERAS-4001 Phase 1 monotherapy data from BOREALIS-1, expected in the second half of 2026.
  • AURORAS-1 Phase 1 monotherapy expansion data and combination dose escalation data, including the panitumumab combination, both expected in the first half of 2027.
  • Initiation of a potentially registration-enabling trial in second line or greater NSCLC, expected in the first half of 2027.
  • Initiation of the Phase 3 pivotal trial in first line PDAC, expected in 2027.
  • Initiation of BOREALIS-1 monotherapy expansion and combination dose escalation cohorts, planned for 2027.
  • Quarterly R&D and G&A expense levels relative to the Q3 2026 figures of $47.2 million and $12.3 million, and the trajectory of cash, cash equivalents, and marketable securities.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities were $947.8 million as of September 30, 2026, compared with $341.8 million as of December 31, 2025 (balance sheet data, unaudited).
  • Working capital was 611,200 (in thousands) as of September 30, 2026, compared with 257,728 (in thousands) as of December 31, 2025.
  • Total assets were 998,936 (in thousands) as of September 30, 2026, compared with 396,154 (in thousands) as of December 31, 2025.
  • Total stockholders' equity was 916,738 (in thousands) as of September 30, 2026, compared with 325,171 (in thousands) as of December 31, 2025.
  • Accumulated deficit was (1,171,059) (in thousands) as of September 30, 2026, compared with (892,209) (in thousands) as of December 31, 2025.
  • In July 2026 the company completed an upsized public offering, which the filing states raised approximately $632.5 million in gross proceeds.
  • The company states that its current cash, cash equivalents, and marketable securities will be sufficient to fund the Key Upcoming Milestones listed in the release.

Analysis

Erasca reported results for the fiscal quarter ended September 30, 2026, a period in which the statements of operations show no revenue line. Total operating expenses rose to 59,521 (in thousands) from 34,546 (in thousands) in the year-earlier quarter, and the net loss widened to $51.3 million, or $(0.15) per share, from $30.6 million, or $(0.11) per share. The main line items moving the loss were R&D, at $47.2 million against $22.5 million, and G&A, at $12.3 million against $10.1 million. The company attributes the R&D increase to clinical trial, preclinical, discovery, personnel and outsourced service costs, and the G&A increase to personnel costs including stock-based compensation.

The nine-month picture is more heavily shaped by a single item. Operating expenses for the nine months ended September 30, 2026 were 295,051 (in thousands), against 108,301 (in thousands) a year earlier, and in-process R&D accounted for 150,000 (in thousands) of that total, compared with 9,500 (in thousands) in the prior-year period. Nine-month net loss was (278,850) (in thousands), or $(0.87) per share, against (95,454) (in thousands), or $(0.34) per share. The filing does not provide a breakdown of the in-process R&D charge beyond the statement line itself.

The balance sheet changed materially over the period. Cash, cash equivalents, and marketable securities were $947.8 million at September 30, 2026, against $341.8 million at December 31, 2025, and stockholders' equity rose to 916,738 (in thousands) from 325,171 (in thousands). The release refers to an upsized public offering completed in July 2026 with approximately $632.5 million in gross proceeds, which is the main identified source of the increase. Management states that current cash, cash equivalents and marketable securities will be sufficient to fund the milestones listed in the release. The filing does not include a cash flow statement, so operating or free cash flow for the period cannot be reported.

Operationally, the company highlighted FDA Fast Track Designation for ERAS-0015 in metastatic pancreatic adenocarcinoma, granted in August 2026, and two presentations at the ENA Symposium in November 2026. It also reported the appointment of a president of research and development and a senior vice president of global pharmacovigilance in August 2026. The milestone schedule runs through 2027 and into 2028, with preliminary ERAS-4001 data expected in the second half of 2026, ERAS-0015 monotherapy and combination data in the first half of 2027, and Phase 3 starts in 2027 and in the second half of 2027 to the first half of 2028. The filing contains no financial guidance for future periods.

The key figures for a reader are the step-up in R&D and G&A, the reported net loss, the $947.8 million cash balance, and the dated milestones. The forward-looking statements also flag the RevMed patent and trade secret allegations and the possibility of trial delays as risks to the schedule.

Management, verbatim

The emerging clinical profile of ERAS-0015 continues to support its potential as a foundational therapy across RAS-mutant cancers, both as a monotherapy and backbone for combination regimens.

Jonathan E. Lim, M.D., Chairman, Chief Executive Officer, and co-founder

With a strengthened balance sheet and experienced R&D leadership, we believe that we are positioned to execute our near-term milestones and advance programs addressing high unmet needs for patients with RAS-mutant cancers.

Jonathan E. Lim, M.D., Chairman, Chief Executive Officer, and co-founder

Not in the filing

stated, not guessed
  • No revenue or collaboration revenue line appears in the statements of operations, so no revenue figure is reported.
  • No prior-quarter (Q2 2026) figures are printed, so all qoq_change and prior_quarter fields are null.
  • No percentage changes are printed for any metric, so all yoy_change fields are null.
  • No segment information is reported.
  • No cash flow statement or operating cash flow, investing cash flow, or free cash flow figures are provided.
  • No share repurchase or dividend activity is reported.
  • The filing does not state whether the figures are GAAP or non-GAAP; statement of operations basis is recorded as GAAP on the assumption that these are the reported statement lines.
  • No stock price reaction, consensus estimates, or analyst expectations are included in the documents.
  • Prior-year figures for the balance sheet are as of December 31, 2025, not the same period of the prior year, so balance sheet prior_year fields are null.
  • The July 2026 offering is described only as approximately $632.5 million in gross proceeds; no net proceeds, share count or pricing details are provided.
  • The previous outlook contained only milestone timing and a cash runway statement, with no numeric guidance for Q3 2026 results, so there is nothing to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readERAS · Second Quarter 2026 · ended June 30, 2026

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

✓Solid quarter

The quarter combined updated preliminary ERAS-0015 clinical data, defined upcoming pipeline milestones, and a strengthened cash position following financings, although operating expenses and net loss increased from the prior-year quarter.

EPS · GAAP
$(0.14)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expensesGAAP$35.9M––
General and administrative expensesGAAP$11.7M––
Net lossGAAP$44.1M––
Net loss per basic shareGAAP$(0.14) per basic share––
Net loss per diluted shareGAAP$(0.14) per diluted share––
Cash, cash equivalents, and marketable securitiesother$384.3M––

Key Upcoming Milestones outlook

  • NoteERAS-0015 Phase 1 monotherapy expansion data expected in the first half of 2027
  • NoteERAS-0015 Phase 1 combination dose escalation data, including panitumumab combination, expected in the first half of 2027
  • NotePotentially registration-enabling trial in 2L+ NSCLC expected to initiate in the first half of 2027
  • NotePhase 3 pivotal trial in 1L PDAC expected to initiate in 2027
  • NotePhase 3 pivotal trial in RASm NSCLC expected to initiate in the second half of 2027 to the first half of 2028
  • NoteERAS-4001 preliminary Phase 1 monotherapy data expected in the second half of 2026
  • NoteInitiation of ERAS-4001 monotherapy expansion cohorts and combination dose escalation cohorts planned for 2027
  • NoteErasca expects its current cash, cash equivalents, and marketable securities (inclusive of the net proceeds received from the July 2026 underwritten offering) will be sufficient to fund the Key Upcoming Milestones set forth above in this press release.

What drove it

  • At the recommended dose for expansion of 32 mg once daily, ERAS-0015 demonstrated a 57% uORR 8wk in 2L+ KRAS G12X PDAC, with ongoing treatment across all responding patients and most enrolled patients.
  • ERAS-0015 reported mostly low-grade treatment-related adverse events, no dose-limiting toxicities, no treatment-related discontinuations, and a median relative dose intensity of 100% at both the 24 mg QD and 32 mg QD RDEs.
  • The company cleared the first 16 mg dose-escalation cohort of ERAS-0015 in combination with panitumumab after demonstrating no DLTs; backfill enrollment is ongoing in the 16 mg combination cohort and dose escalation is continuing in the 24 mg combination cohort.
  • R&D expense increased primarily due to clinical trials, preclinical studies, discovery activities, outsourced services, consulting fees, and personnel costs, including stock-based compensation expense.
  • G&A expense increased primarily due to personnel costs, including stock-based compensation expense, and legal costs.

Concerns

  • Net loss was $44.1 million for the quarter ended June 30, 2026, compared to $33.9 million for the quarter ended June 30, 2025.
  • R&D expenses were $35.9 million for the quarter ended June 30, 2026, compared to $21.2 million for the quarter ended June 30, 2025.
  • The company stated that interim, topline and preliminary clinical-trial results are not necessarily indicative of final results and may materially change as enrollment and follow-up continue.
  • Potentially registration-enabling trials may be delayed based on FDA feedback or requirements, and successful planned trials may not support regulatory approval.

What to watch

  • ERAS-4001 preliminary Phase 1 monotherapy data expected in the second half of 2026.
  • ERAS-0015 Phase 1 monotherapy expansion data expected in the first half of 2027.
  • ERAS-0015 Phase 1 combination dose escalation data, including the panitumumab combination, expected in the first half of 2027.
  • Potential initiation of the ERAS-0015 2L+ NSCLC potentially registration-enabling trial in the first half of 2027.
  • Phase 3 pivotal trial initiation plans for 1L PDAC in 2027 and RASm NSCLC in the second half of 2027 to the first half of 2028.
  • Use of the July 2026 underwritten-offering net proceeds and the company's stated ability to fund the listed upcoming milestones.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities were $384.3 million as of June 30, 2026, compared to $341.8 million as of December 31, 2025.
  • In July 2026, Erasca completed an upsized public offering, raising approximately $632.5 million in gross proceeds.
  • Erasca's January 2026 upsized public offering raised approximately $258.8 million in gross proceeds.

Analysis

Erasca's second-quarter update centered on clinical progress rather than commercial performance. ERAS-0015 produced a 57% uORR 8wk at the 32 mg once-daily recommended dose for expansion in 2L+ KRAS G12X PDAC. The company also reported ongoing treatment across all responding patients and most enrolled patients, alongside mostly low-grade treatment-related adverse events, no dose-limiting toxicities, no treatment-related discontinuations, and a median relative dose intensity of 100% at the 24 mg QD and 32 mg QD RDEs.

The development plan broadened during July. The company cleared the first 16 mg ERAS-0015 plus panitumumab dose-escalation cohort with no DLTs, is enrolling a backfill cohort at that dose, and is continuing escalation in the 24 mg combination cohort. Management identified ERAS-0015 monotherapy and combination data in the first half of 2027 as key next disclosures, while ERAS-4001 preliminary Phase 1 monotherapy data are expected in the second half of 2026.

Expenses and loss increased from the comparable prior-year period. R&D expenses were $35.9 million versus $21.2 million, driven by clinical trials, preclinical studies, discovery activities, outsourced services, consulting fees, and personnel costs. G&A expenses were $11.7 million versus $9.5 million. Net loss was $44.1 million, or $(0.14) per basic and diluted share, compared with $33.9 million, or $(0.12) per basic and diluted share. The release does not provide prior-quarter operating results, so quarter-over-quarter changes cannot be assessed from the filing.

Liquidity strengthened through financing activity. Cash, cash equivalents, and marketable securities were $384.3 million as of June 30, 2026, compared with $341.8 million as of December 31, 2025. Erasca subsequently completed an upsized public offering in July that raised approximately $632.5 million in gross proceeds, following an approximately $258.8 million gross-proceeds offering in January. The company stated that current cash, cash equivalents, and marketable securities, inclusive of net July offering proceeds, will be sufficient to fund the listed upcoming milestones.

The central execution issues are conversion of preliminary ERAS-0015 activity into subsequent data sets and progress toward the planned potentially registration-enabling programs in NSCLC, PDAC, and RASm NSCLC. The company explicitly notes that preliminary results may change with additional enrollment and follow-up, and that FDA feedback or requirements could delay planned potentially registration-enabling trials or require additional data.

Management, verbatim

Updated clinical data from our U.S. trial further bolster our excitement for advancing ERAS-0015, with compelling monotherapy activity in 2L+ KRAS G12X pancreatic cancer, previously disclosed encouraging data in 2L+ KRAS G12X lung cancer, sustained tolerability with longer follow-up, and promising combination potential.

Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder

Not in the filing

stated, not guessed
  • Total revenue
  • Revenue by segment
  • Gross profit and gross margin
  • Operating income or loss
  • Non-GAAP financial measures, including non-GAAP operating income, net income or loss, and EPS
  • Operating cash flow
  • Free cash flow
  • Debt balance
  • Dividend payments
  • Share repurchases
  • Tax rate
  • Detailed cash-flow statement items
  • Prior-quarter R&D expenses, G&A expenses, net loss, and EPS
  • Percentage year-over-year and quarter-over-quarter changes for reported financial metrics
  • Financial guidance for revenue, gross margin, operating expenses, or tax rate
  • Previous-quarter outlook for comparison

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ERAS earnings dates

When is Erasca's next earnings date?
AlphAI has no date for ERAS yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.